Amgen and CytomX remove disguised T-cell engager and axe the asset

March 9, 2025

Gedatolisib from Celcuity outperforms Piqray from Novartis in phase 3 research

May 6, 2026

Regeneron receives FDA approval for longer-lasting vision loss medication

August 23, 2023

Must Read

The Rise of AI-Native Biotech Companies

July 9, 2026

Why Every Pharma Company Is Becoming a Technology Company

July 9, 2026

Novartis Set to Buy UK Biotech Myricx For Over $1.1B

July 9, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Early research shows that Lilly’s Verve strategy is successful in lowering cholesterol

Kailera Details Nasdaq IPO Plans to Raise Up to $528.5 Million for Obesity Drug Development

Avalyn Files for IPO to Fund Late-Stage Development of Inhaled Lung Disease Therapies

Merck Pays $20 Million Upfront to Access Quotient’s Somatic Genomics Platform for IBD Research

Phase 3 KRYSTAL-10 Study Fails to Meet Primary Endpoints for Krazati in Metastatic Colorectal Cancer

Kailera and Hengrui Report Phase 3 Results for Oral GLP-1 Drug in Obesity and Type 2 Diabetes

Phase 3 NSCLC study for Pfizer’s first novel ADC from the acquisition of Seagen fails

BridgeBio Advances Attruby Launch and Three Late-Stage Drug Programs as It Secures New Investment

Novartis Set to Buy UK Biotech Myricx For Over $1.1B

In its biggest-ever transaction, Vertex pays $10 billion to buy endocrine disease expert Crinetics

Orca Bio Gets FDA Green Light For Tregzi; IPO a Real Possibility

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

The Rise of AI-Native Biotech Companies

Why Every Pharma Company Is Becoming a Technology Company

Top 10 Reasons Precision Medicine Requires Better Data Integration

Why Pharma Supply Chains Need a Resilience-First Strategy

Tag: tafamidis Patent

Pfizer EU Tafamidis Patent Withdrawal

Editor Picks

Amgen and CytomX remove disguised T-cell engager and axe the asset

Gedatolisib from Celcuity outperforms Piqray from Novartis in phase 3 research

Regeneron receives FDA approval for longer-lasting vision loss medication

Must Read

The Rise of AI-Native Biotech Companies

Why Every Pharma Company Is Becoming a Technology Company

Novartis Set to Buy UK Biotech Myricx For Over $1.1B

Hot Topics

About Us

Follow Us